Egrifta (Tesamorelin) Cancer Risk Signal Review
A board-reviewed, primary-literature analysis of the tesamorelin cancer risk signal: what the clinical trials show, what the IGF-1 biology means, and how prescribers should monitor patients receiving Egrifta.